Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar

Haggar FA and Boushey RP: Colorectal cancer epidemiology: Incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg. 22:191–197. 2009. View Article : Google Scholar

Dušek L, Mužík J, Malúšková D and Šnajdrová L: Epidemiology of colorectal cancer: International comparisonInstitute of Biostatistics and Analyses. Masaryk University; Brno, Czech Republic:

Bardhan K and Liu K: Epigenetics and colorectal cancer pathogenesis. Cancers (Basel). 5:676–713. 2013. View Article : Google Scholar

Tsiaoussis J, Vassilopoulou L, Nikolouzakis T, Rakitskii VN, Vakonaki E, Fragkiadaki P, Stivaktakis P and Tsatsakis AM: Biomolecular profile of colorectal cancer - the role of telomerase as a potent biomarker. Farmacia. 65:643–659. 2017.

Souglakos J, Philips J, Wang R, Marwah S, Silver M, Tzardi M, Silver J, Ogino S, Hooshmand S, Kwak E, et al: Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br J Cancer. 101:465–472. 2009. View Article : Google Scholar

Migliore L, Migheli F, Spisni R and Coppedè F: Genetics, cytogenetics, and epigenetics of colorectal cancer. J Biomed Biotechnol. 2011:7923622011. View Article : Google Scholar

Gonzalez-Pons M and Cruz-Correa M: Colorectal cancer biomarkers: Where are we now? BioMed Res Int. 2015:1490142015. View Article : Google Scholar

Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B and Starling N: Colorectal cancer. Lancet. 375:1030–1047. 2010. View Article : Google Scholar

Kuipers EJ, Rösch T and Bretthauer M: Colorectal cancer screening - optimizing current strategies and new directions. Nat Rev Clin Oncol. 10:130–142. 2013. View Article : Google Scholar

Labianca R and Merelli B: Screening and diagnosis for colorectal cancer: Present and future. Tumori. 96:889–901. 2010. View Article : Google Scholar

Mahmud A, Poon R and Jonker D: PET imaging in anal canal cancer: A systematic review and meta-analysis. Br J Radiol. 90:201703702017. View Article : Google Scholar

Paspulati RM and Gupta A: PET/MR imaging in cancers of the gastrointestinal tract. PET Clin. 11:403–423. 2016. View Article : Google Scholar

Bond JH: Fecal occult blood test screening for colorectal cancer. Gastrointest Endosc Clin N Am. 12:11–21. 2002. View Article : Google Scholar

Siegel R, Desantis C and Jemal A: Colorectal cancer statistics, 2014. CA Cancer J Clin. 64:104–117. 2014. View Article : Google Scholar

Ahlquist DA: Molecular detection of colorectal neoplasia. Gastroenterology. 138:2127–2139. 2010. View Article : Google Scholar

Shah R, Jones E, Vidart V, Kuppen PJ, Conti JA and Francis NK: Biomarkers for early detection of colorectal cancer and polyps: Systematic review. Cancer Epidemiol Biomarkers Prev. 23:1712–1728. 2014. View Article : Google Scholar

Alix-Panabières C and Pantel K: Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov. 6:479–491. 2016. View Article : Google Scholar

Shastri YM, Loitsch S, Hoepffner N, Povse N, Hanisch E, Rösch W, Mössner J and Stein JM: Comparison of an established simple office-based immunological FOBT with fecal tumor pyruvate kinase type M2 (M2-PK) for colorectal cancer screening: Prospective multicenter study. Am J Gastroenterol. 103:1496–1504. 2008. View Article : Google Scholar

Takai T, Kanaoka S, Yoshida K, Hamaya Y, Ikuma M, Miura N, Sugimura H, Kajimura M and Hishida A: Fecal cyclooxygenase 2 plus matrix metalloproteinase 7 mRNA assays as a marker for colorectal cancer screening. Cancer Epidemiol Biomarkers Prev. 18:1888–1893. 2009. View Article : Google Scholar

Huang Z, Huang D, Ni S, Peng Z, Sheng W and Du X: Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer. 127:118–126. 2010. View Article : Google Scholar

Wu CW, Ng SS, Dong YJ, Ng SC, Leung WW, Lee CW, Wong YN, Chan FK, Yu J and Sung JJ: Detection of miR-92a and miR-21 in stool samples as potential screening biomarkers for colorectal cancer and polyps. Gut. 61:739–745. 2012. View Article : Google Scholar

Pan C, Yan X, Li H, Huang L, Yin M, Yang Y, Gao R, Hong L, Ma Y, Shi C, et al: Systematic literature review and clinical validation of circulating microRNAs as diagnostic biomarkers for colorectal cancer. Oncotarget. 8:68317–68328. 2017. View Article : Google Scholar

Kanaan Z, Roberts H, Eichenberger MR, Billeter A, Ocheretner G, Pan J, Rai SN, Jorden J, Williford A and Galandiuk S: A plasma microRNA panel for detection of colorectal adenomas: A step toward more precise screening for colorectal cancer. Ann Surg. 258:400–408. 2013. View Article : Google Scholar

Imperiale TF, Ransohoff DF, Itzkowitz SH, Levin TR, Lavin P, Lidgard GP, Ahlquist DA and Berger BM: Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 370:1287–1297. 2014. View Article : Google Scholar

Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA and Ross ME: Colorectal Cancer Study Group: Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med. 351:2704–2714. 2004. View Article : Google Scholar

Bayrak R, Yenidünya S and Haltas H: Cytokeratin 7 and cytokeratin 20 expression in colorectal adenocarcinomas. Pathol Res Pract. 207:156–160. 2011. View Article : Google Scholar

Righi A, Betts CM, Marchetti C, Marucci G, Montebugnoli L, Prati C, Eusebi LH, Muzzi L, Ragazzini T and Foschini MP: Merkel cells in the oral mucosa. Int J Surg Pathol. 14:206–211. 2006. View Article : Google Scholar

Stenling R, Lindberg J, Rutegård J and Palmqvist R: Altered expression of CK7 and CK20 in preneoplastic and neoplastic lesions in ulcerative colitis. APMIS. 115:1219–1226. 2007. View Article : Google Scholar

Radović S, Selak I, Babić M, Vukobrat-Bijedić Z and Knezević Z: Anti-cytokeratin 7: A positive marker for epithelial dysplasia in flat bowel mucosa. Bosn J Basic Med Sci. 4:24–30. 2004.

Gurzu S and Jung I: Aberrant pattern of the cytokeratin 7/cytokeratin 20 immunophenotype in colorectal adenocarcinomas with BRAF mutations. Pathol Res Pract. 208:163–166. 2012. View Article : Google Scholar

Chu P, Wu E and Weiss LM: Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: A survey of 435 cases. Mod Pathol. 13:962–972. 2000. View Article : Google Scholar

Miettinen M, Nobel MP, Tuma BT and Kovatich AJ: Keratin 17: Immunohistochemical mapping of its distribution in human epithelial tumors and its potential applications. Appl Immunohistochem. 5:152–159. 1997. View Article : Google Scholar

Hernandez BY, Frierson HF Jr, Moskaluk CA, Li YJ, Clegg L, Cote TR, McCusker ME, Hankey BF, Edwards BK and Goodman MT: CK20 and CK7 protein expression in colorectal cancer: Demonstration of the utility of a population-based tissue microarray. Hum Pathol. 36:275–281. 2005. View Article : Google Scholar

Silberg DG, Swain GP, Suh ER and Traber PG: Cdx1 and cdx2 expression during intestinal development. Gastroenterology. 119:961–971. 2000. View Article : Google Scholar

Moskaluk CA, Zhang H, Powell SM, Cerilli LA, Hampton GM and Frierson HF Jr: Cdx2 protein expression in normal and malignant human tissues: An immunohistochemical survey using tissue microarrays. Mod Pathol. 16:913–919. 2003. View Article : Google Scholar

Werling RW, Yaziji H, Bacchi CE and Gown AM: CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: An immunohistochemical survey of 476 primary and metastatic carcinomas. Am J Surg Pathol. 27:303–310. 2003. View Article : Google Scholar

Zheng J, He S, Qi J, Wang X, Yu J, Wu Y, Gao Q, Wang K and Sun X: Targeted CDX2 expression inhibits aggressive phenotypes of colon cancer cells in vitro and in vivo. Int J Oncol. 51:478–488. 2017. View Article : Google Scholar

Bretscher A and Weber K: Villin: The major microfilament-associated protein of the intestinal microvillus. Proc Natl Acad Sci USA. 76:2321–2325. 1979. View Article : Google Scholar

Patnaik S, George SP, Pham E, Roy S, Singh K, Mariadason JM and Khurana S: By moonlighting in the nucleus, villin regulates epithelial plasticity. Mol Biol Cell. 27:535–548. 2016. View Article : Google Scholar

Kuroda N and Yorita K: Colon cancer with micropapillary carcinoma component: A clinopathologic study of 9 cases. Pol J Pathol. 68:102–108. 2017. View Article : Google Scholar

Bacchi CE and Gown AM: Distribution and pattern of expression of villin, a gastrointestinal-associated cytoskeletal protein, in human carcinomas: A study employing paraffin-embedded tissue. Lab Invest. 64:418–424. 1991.

Willert K and Nusse R: Beta-catenin: A key mediator of Wnt signaling. Curr Opin Genet Dev. 8:95–102. 1998. View Article : Google Scholar

Wang JL, Qi Z, Li YH, Zhao HM, Chen YG and Fu W: TGFβ induced factor homeobox 1 promotes colorectal cancer development through activating Wnt/β-catenin signaling. Oncotarget. 8:70214–70225. 2017.

Clevers H: Wnt/β-catenin signaling in development and disease. Cell. 127:469–480. 2006. View Article : Google Scholar

Sheahan K, O'Brien MJ, Burke B, Dervan PA, O'Keane JC, Gottlieb LS and Zamcheck N: Differential reactivities of carcinoembryonic antigen (CEA) and CEA-related monoclonal and polyclonal antibodies in common epithelial malignancies. Am J Clin Pathol. 94:157–164. 1990. View Article : Google Scholar

Zhou M, Chinnaiyan AM, Kleer CG, Lucas PC and Rubin MA: Alpha-methylacyl-CoA racemase: A novel tumor marker over-expressed in several human cancers and their precursor lesions. Am J Surg Pathol. 26:926–931. 2002. View Article : Google Scholar

Tan E, Gouvas N, Nicholls RJ, Ziprin P, Xynos E and Tekkis PP: Diagnostic precision of carcinoembryonic antigen in the detection of recurrence of colorectal cancer. Surg Oncol. 18:15–24. 2009. View Article : Google Scholar

Andrianifahanana M, Moniaux N and Batra SK: Regulation of mucin expression: Mechanistic aspects and implications for cancer and inflammatory diseases. Biochim Biophys Acta. 1765:189–222. 2006.

Hanski C, Hofmeier M, Schmitt-Gräff A, Riede E, Hanski ML, Borchard F, Sieber E, Niedobitek F, Foss HD, Stein H and Riecken EO: Overexpression or ectopic expression of MUC2 is the common property of mucinous carcinomas of the colon, pancreas, breast, and ovary. J Pathol. 182:385–391. 1997. View Article : Google Scholar

Zlatian OM, Comănescu MV, Roşu AF, Roşu L, Cruce M, Găman AE, Călina CD and Sfredel V: Histochemical and immunohistochemical evidence of tumor heterogeneity in colorectal cancer. Rom J Morphol Embryol. 56:175–181. 2015.

Park SY, Lee HS, Choe G, Chung JH and Kim WH: Clinicopathological characteristics, microsatellite instability, and expression of mucin core proteins and p53 in colorectal mucinous adenocarcinomas in relation to location. Virchows Arch. 449:40–47. 2006. View Article : Google Scholar

King RJ, Yu F and Singh PK: Genomic alterations in mucins across cancers. Oncotarget. 8:67152–67168. 2017. View Article : Google Scholar

Wang H, Jin S, Lu H, Mi S, Shao W, Zuo X, Yin H, Zeng S, Shimamoto F and Qi G: Expression of survivin, MUC2 and MUC5 in colorectal cancer and their association with clinicopathological characteristics. Oncol Lett. 14:1011–1016. 2017. View Article : Google Scholar

Dantzig AH, Hoskins JA, Tabas LB, Bright S, Shepard RL, Jenkins IL, Duckworth DC, Sportsman JR, Mackensen D, Rosteck PR Jr, et al: Association of intestinal peptide transport with a protein related to the cadherin superfamily. Science. 264:430–433. 1994. View Article : Google Scholar

Su MC, Yuan RH, Lin CY and Jeng YM: Cadherin-17 is a useful diagnostic marker for adenocarcinomas of the digestive system. Mod Pathol. 21:1379–1386. 2008. View Article : Google Scholar

Panarelli NC, Yantiss RK, Yeh MM, Liu Y and Chen YT: Tissue-specific cadherin CDH17 is a useful marker of gastrointestinal adenocarcinomas with higher sensitivity than CDX2. Am J Clin Pathol. 138:211–222. 2012. View Article : Google Scholar

Stănculescu D, Mărgăritescu C, Stepan A and Mitruţ AO: E-cadherin in gastric carcinomas related to histological prognostic parameters. Rom J Morphol Embryol. 52 Suppl:1107–1112. 2011.

Bian T, Zhao J, Feng J, Zhang Q, Qian L, Liu J, Jiang D, Liu Y and Zhang J: Combination of cadherin-17 and SATB homeobox 2 serves as potential optimal makers for the differential diagnosis of pulmonary enteric adenocarcinoma and metastatic colorectal adenocarcinoma. Oncotarget. 8:63442–63452. 2017. View Article : Google Scholar

Tian X, Liu M, Zhu Q, Tan J, Liu W, Wang Y, Chen W, Zou Y, Cai Y, Han Z and Huang X: Down-regulation of liver-intestine cadherin enhances noscapine-induced apoptosis in human colon cancer cells. Expert Rev Anticancer Ther. 17:857–863. 2017. View Article : Google Scholar

Magnusson K, de Wit M, Brennan DJ, Johnson LB, McGee SF, Lundberg E, Naicker K, Klinger R, Kampf C, Asplund A, et al: SATB2 in combination with cytokeratin 20 identifies over 95% of all colorectal carcinomas. Am J Surg Pathol. 35:937–948. 2011. View Article : Google Scholar

Valori R, Rey JF, Atkin WS, Bretthauer M, Senore C, Hoff G, Kuipers EJ, Altenhofen L, Lambert R and Minoli G: International Agency for Research on Cancer: European guidelines for quality assurance in colorectal cancer screening and diagnosis First Edition - quality assurance in endoscopy in colorectal cancer screening and diagnosis. Endoscopy. 44 Suppl 3:SE88–SE105. 2012.

Lieberman DA and Weiss DG: Veterans Affairs Cooperative Study Group 380: One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. N Engl J Med. 345:555–560. 2001. View Article : Google Scholar

Young GP, Symonds EL, Allison JE, Cole SR, Fraser CG, Halloran SP, Kuipers EJ and Seaman HE: Advances in fecal occult blood tests: The FIT revolution. Dig Dis Sci. 60:609–622. 2015. View Article : Google Scholar

Whitlock EP, Lin J, Liles E, Beil T, Fu R, O'Connor E, Thompson RN and Cardenas T: Screening for Colorectal Cancer: An Updated Systematic ReviewAgency for Healthcare Research and Quality. Rockville, MD: 2008

Morikawa T, Kato J, Yamaji Y, Wada R, Mitsushima T and Shiratori Y: A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology. 129:422–428. 2005. View Article : Google Scholar

Gupta AK, Melton LJ III, Petersen GM, Timmons LJ, Vege SS, Harmsen WS, Diehl NN, Zinsmeister AR and Ahlquist DA: Changing trends in the incidence, stage, survival, and screen-detection of colorectal cancer: A population-based study. Clin Gastroenterol Hepatol. 3:150–158. 2005. View Article : Google Scholar

Puccini A, Berger MD, Naseem M, Tokunaga R, Battaglin F, Cao S, Hanna DL, McSkane M, Soni S, Zhang W and Lenz HJ: Colorectal cancer: Epigenetic alterations and their clinical implications. Biochim Biophys Acta. 1868:439–448. 2017.

Losso GM, Moraes RS, Gentili AC and Messias-Reason IT: Microsatellite instability - MSI markers (BAT26, BAT25, D2S123, D5S346, D17S250) in rectal cancer. Arq Bras Cir Dig. 25:240–244. 2012. View Article : Google Scholar

de la Chapelle A and Hampel H: Clinical relevance of microsatellite instability in colorectal cancer. J Clin Oncol. 28:3380–3387. 2010. View Article : Google Scholar

Merok MA, Ahlquist T, Røyrvik EC, Tufteland KF, Hektoen M, Sjo OH, Mala T, Svindland A, Lothe RA and Nesbakken A: Microsatellite instability has a positive prognostic impact on stage II colorectal cancer after complete resection: Results from a large, consecutive Norwegian series. Ann Oncol. 24:1274–1282. 2013. View Article : Google Scholar

Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Rüschoff J, Fishel R, Lindor NM, Burgart LJ, Hamelin R, et al: Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 96:261–268. 2004. View Article : Google Scholar

Laghi L, Bianchi P and Malesci A: Differences and evolution of the methods for the assessment of microsatellite instability. Oncogene. 27:6313–6321. 2008. View Article : Google Scholar

Roth AD, Tejpar S, Yan P, Fiocca R, Dietrich D, Delorenzi M, Labianca R, Cunningham D, Van Cutsem E and Bosman F: Stage-specific prognostic value of molecular markers in colon cancer: Results of the translational study on the PETACC 3-EORTC 40993-SAKK 60–00 trial. J Clin Oncol. 27 15 Suppl:40022009.

Koopman M, Kortman GA, Mekenkamp L, Ligtenberg MJ, Hoogerbrugge N, Antonini NF, Punt CJ and van Krieken JH: Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer. 100:266–273. 2009. View Article : Google Scholar

Ulamec M and Krušlin B: Colorectal cancer, novel biomarkers and immunohistochemistry - an overview. Rad Med Sci. 520:41–49. 2014.

Hashimoto Y, Zumwalt TJ and Goel A: DNA methylation patterns as noninvasive biomarkers and targets of epigenetic therapies in colorectal cancer. Epigenomics. 8:685–703. 2016. View Article : Google Scholar

Jair KW, Bachman KE, Suzuki H, Ting AH, Rhee I, Yen RW, Baylin SB and Schuebel KE: De novo CpG island methylation in human cancer cells. Cancer Res. 66:682–692. 2006. View Article : Google Scholar

Beggs AD, Jones A, El-Bahrawy M, Abulafi M, Hodgson SV and Tomlinson IP: Whole-genome methylation analysis of benign and malignant colorectal tumours. J Pathol. 229:697–704. 2013. View Article : Google Scholar

Toiyama Y, Okugawa Y and Goel A: DNA methylation and microRNA biomarkers for noninvasive detection of gastric and colorectal cancer. Biochem Biophys Res Commun. 455:43–57. 2014. View Article : Google Scholar

Lind GE, Danielsen SA, Ahlquist T, Merok MA, Andresen K, Skotheim RI, Hektoen M, Rognum TO, Meling GI, Hoff G, et al: Identification of an epigenetic biomarker panel with high sensitivity and specificity for colorectal cancer and adenomas. Mol Cancer. 10:852011. View Article : Google Scholar

Cheung AF, Carter AM, Kostova KK, Woodruff JF, Crowley D, Bronson RT, Haigis KM and Jacks T: Complete deletion of Apc results in severe polyposis in mice. Oncogene. 29:1857–1864. 2010. View Article : Google Scholar

Dow LE, O'Rourke KP, Simon J, Tschaharganeh DF, van Es JH, Clevers H and Lowe SW: Apc restoration promotes cellular differentiation and reestablishes crypt homeostasis in colorectal cancer. Cell. 161:1539–1552. 2015. View Article : Google Scholar

Liang J, Lin C, Hu F, Wang F, Zhu L, Yao X, Wang Y and Zhao Y: APC polymorphisms and the risk of colorectal neoplasia: A HuGE review and meta-analysis. Am J Epidemiol. 177:1169–1179. 2013. View Article : Google Scholar

Docea AO, Mitruţ P, Grigore D, Pirici D, Călina DC and Gofiţă E: Immunohistochemical expression of TGF beta (TGF-β), TGF beta receptor 1 (TGFBR1), and Ki67 in intestinal variant of gastric adenocarcinomas. Rom J Morphol Embryol. 53 Suppl:683–692. 2012.

Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD and Knippers R: DNA fragments in the blood plasma of cancer patients: Quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 61:1659–1665. 2001.

Frattini M, Gallino G, Signoroni S, Balestra D, Lusa L, Battaglia L, Sozzi G, Bertario L, Leo E, Pilotti S and Pierotti MA: Quantitative and qualitative characterization of plasma DNA identifies primary and recurrent colorectal cancer. Cancer Lett. 263:170–181. 2008. View Article : Google Scholar

Diehl F, Li M, Dressman D, He Y, Shen D, Szabo S, Diaz LA Jr, Goodman SN, David KA, Juhl H, et al: Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci USA. 102:16368–16373. 2005. View Article : Google Scholar

Tänzer M, Balluff B, Distler J, Hale K, Leodolter A, Röcken C, Molnar B, Schmid R, Lofton-Day C, Schuster T and Ebert MP: Performance of epigenetic markers SEPT9 and ALX4 in plasma for detection of colorectal precancerous lesions. PLoS One. 5:e90612010. View Article : Google Scholar

Danese E and Montagnana M: Epigenetics of colorectal cancer: Emerging circulating diagnostic and prognostic biomarkers. Ann Transl Med. 5:2792017. View Article : Google Scholar

Ahlquist DA, Harrington JJ, Burgart LJ and Roche PC: Morphometric analysis of the ‘mucocellular layer’ overlying colorectal cancer and normal mucosa: Relevance to exfoliation and stool screening. Hum Pathol. 31:51–57. 2000. View Article : Google Scholar

Chen WD, Han ZJ, Skoletsky J, Olson J, Sah J, Myeroff L, Platzer P, Lu S, Dawson D, Willis J, et al: Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J Natl Cancer Inst. 97:1124–1132. 2005. View Article : Google Scholar

Itzkowitz S, Brand R, Jandorf L, Durkee K, Millholland J, Rabeneck L, Schroy PC III, Sontag S, Johnson D, Markowitz S, et al: A simplified, noninvasive stool DNA test for colorectal cancer detection. Am J Gastroenterol. 103:2862–2870. 2008. View Article : Google Scholar

Lee RC, Feinbaum RL and Ambros V: The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 75:843–854. 1993. View Article : Google Scholar

Wightman B, Ha I and Ruvkun G: Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell. 75:855–862. 1993. View Article : Google Scholar

He L and Hannon GJ: MicroRNAs: Small RNAs with a big role in gene regulation. Nat Rev Genet. 5:522–531. 2004. View Article : Google Scholar

Mendell JT: MicroRNAs: Critical regulators of development, cellular physiology and malignancy. Cell Cycle. 4:1179–1184. 2005. View Article : Google Scholar

Vasudevan S, Tong Y and Steitz JA: Switching from repression to activation: MicroRNAs can up-regulate translation. Science. 318:1931–1934. 2007. View Article : Google Scholar

Creemers EE, Tijsen AJ and Pinto YM: Circulating microRNAs: Novel biomarkers and extracellular communicators in cardiovascular disease? Circ Res. 110:483–495. 2012. View Article : Google Scholar

Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF, Mitchell PS, Bennett CF, Pogosova-Agadjanyan EL, Stirewalt DL, et al: Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci USA. 108:5003–5008. 2011. View Article : Google Scholar

Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD and Remaley AT: MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol. 13:423–433. 2011. View Article : Google Scholar

Toiyama Y, Takahashi M, Hur K, Nagasaka T, Tanaka K, Inoue Y, Kusunoki M, Boland CR and Goel A: Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. J Natl Cancer Inst. 105:849–859. 2013. View Article : Google Scholar

Ng EK, Chong WW, Jin H, Lam EK, Shin VY, Yu J, Poon TC, Ng SS and Sung JJ: Differential expression of microRNAs in plasma of patients with colorectal cancer: A potential marker for colorectal cancer screening. Gut. 58:1375–1381. 2009. View Article : Google Scholar

Carter JV, Galbraith NJ, Yang D, Burton JF, Walker SP and Galandiuk S: Blood-based microRNAs as biomarkers for the diagnosis of colorectal cancer: A systematic review and meta-analysis. Br J Cancer. 116:762–774. 2017. View Article : Google Scholar

Okugawa, Grady WM and Goel A: Epigenetic alterations in colorectal cancer: Emerging biomarkers. Gastroenterology. 149:1204–1225.e12. 2015. View Article : Google Scholar

Chen M, Lin M and Wang X: Over expression of miR-19a inhibits colorectal cancer angiogenesis by suppressing KRAS expression. Oncol Rep. 39:619–626. 2018.

Link A, Balaguer F, Shen Y, Nagasaka T, Lozano JJ, Boland CR and Goel A: Fecal microRNAs as novel biomarkers for colon cancer screening. Cancer Epidemiol Biomarkers Prev. 19:1766–1774. 2010. View Article : Google Scholar

Zhu Y, Xu A, Li J, Fu J, Wang G, Yang Y, Cui L and Sun J: Fecal miR-29a and miR-224 as the noninvasive biomarkers for colorectal cancer. Cancer Biomark. 16:259–264. 2016. View Article : Google Scholar

Masuda T, Hayashi N, Kuroda Y, Ito S, Eguchi H and Mimori K: MicroRNAs as biomarkers in colorectal cancer. Cancers (Basel). 9:1242017. View Article : Google Scholar

Edge SB and Compton CC: The American Joint Committee on Cancer: The 7th edition of the AJCC Cancer Staging Manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010. View Article : Google Scholar

Perez RO, Bresciani BH, Bresciani C, Proscurshim I, Kiss D, Gama-Rodrigues J, Pereira DD, Rawet V, Cecconnello I and Habr-Gama A: Mucinous colorectal adenocarcinoma: Influence of mucin expression (Muc1, 2 and 5) on clinico-pathological features and prognosis. Int J Colorectal Dis. 23:757–765. 2008. View Article : Google Scholar

Wang S, Zhou J, Wang XY, Hao JM, Chen JZ, Zhang XM, Jin H, Liu L, Zhang YF, Liu J, et al: Down-regulated expression of SATB2 is associated with metastasis and poor prognosis in colorectal cancer. J Pathol. 219:114–122. 2009. View Article : Google Scholar

Eberhard J, Gaber A, Wangefjord S, Nodin B, Uhlén M, Lindquist Ericson K and Jirström K: A cohort study of the prognostic and treatment predictive value of SATB2 expression in colorectal cancer. Br J Cancer. 106:931–938. 2012. View Article : Google Scholar

Bae JM, Lee TH, Cho NY, Kim TY and Kang GH: Loss of CDX2 expression is associated with poor prognosis in colorectal cancer patients. World J Gastroenterol. 21:1457–1467. 2015. View Article : Google Scholar

Falchook GS and Kurzrock R: VEGF and dual-EGFR inhibition in colorectal cancer. Cell Cycle. 14:1129–1130. 2015. View Article : Google Scholar

Li D, Yan D, Tang H, Zhou C, Fan J, Li S, Wang X, Xia J, Huang F, Qiu G and Peng Z: IMP3 is a novel prognostic marker that correlates with colon cancer progression and pathogenesis. Ann Surg Oncol. 16:3499–3506. 2009. View Article : Google Scholar

Takahashi H, Ishikawa T, Ishiguro M, Okazaki S, Mogushi K, Kobayashi H, Iida S, Mizushima H, Tanaka H, Uetake H and Sugihara K: Prognostic significance of Traf2- and Nck-interacting kinase (TNIK) in colorectal cancer. BMC Cancer. 15:7942015. View Article : Google Scholar

Spandidos DA, Glarakis IS, Kotsinas A, Ergazaki M and Kiaris H: Ras oncogene activation in benign and malignant colorectal tumours. Tumori. 81 Suppl:7–11. 1995.

Kiaris H and Spandidos D: Mutations of ras genes in human tumors (Review). Int J Oncol. 7:413–421. 1995.

Rui YY, Zhang D, Zhou ZG, Wang C, Yang L, Yu YY and Chen HN: Can K-ras gene mutation be utilized as prognostic biomarker for colorectal cancer patients receiving chemotherapy? A meta-analysis and systematic review. PLoS One. 8:e779012013. View Article : Google Scholar

Andreyev HJN, Norman AR, Cunningham D, Oates JR and Clarke PA: Kirsten ras mutations in patients with colorectal cancer: The multicenter ‘RASCAL’ study. J Natl Cancer Inst. 90:675–684. 1998. View Article : Google Scholar

Andreyev HJN, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ, Young J, Walsh T, Ward R, Hawkins N, et al: Kirsten ras mutations in patients with colorectal cancer: The ‘RASCAL II’ study. Br J Cancer. 85:692–696. 2001. View Article : Google Scholar

Wang Y, Velho S, Vakiani E, Peng S, Bass AJ, Chu GC, Gierut J, Bugni JM, Der CJ, Philips M, et al: Mutant N-RAS protects colorectal cancer cells from stress-induced apoptosis and contributes to cancer development and progression. Cancer Discov. 3:294–307. 2013. View Article : Google Scholar

Russo A, Bazan V, Iacopetta B, Kerr D, Soussi T and Gebbia N: TP53-CRC Collaborative Study Group: The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: Influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol. 23:7518–7528. 2005. View Article : Google Scholar

French AJ, Sargent DJ, Burgart LJ, Foster NR, Kabat BF, Goldberg R, Shepherd L, Windschitl HE and Thibodeau SN: Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. Clin Cancer Res. 14:3408–3415. 2008. View Article : Google Scholar

Toon CW, Chou A, DeSilva K, Chan J, Patterson J, Clarkson A, Sioson L, Jankova L and Gill AJ: BRAFV600E immunohistochemistry in conjunction with mismatch repair status predicts survival in patients with colorectal cancer. Mod Pathol. 27:644–650. 2014. View Article : Google Scholar

Zlobec I, Bihl MP, Schwarb H, Terracciano L and Lugli A: Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis. Int J Cancer. 127:367–380. 2010.

Ogino S, Shima K, Meyerhardt JA, McCleary NJ, Ng K, Hollis D, Saltz LB, Mayer RJ, Schaefer P, Whittom R, et al: Predictive and prognostic roles of BRAF mutation in stage III colon cancer: Results from intergroup trial CALGB 89803. Clin Cancer Res. 18:890–900. 2012. View Article : Google Scholar

Gryfe R, Kim H, Hsieh ET, Aronson MD, Holowaty EJ, Bull SB, Redston M and Gallinger S: Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med. 342:69–77. 2000. View Article : Google Scholar

Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, Hamilton SR, Laurent-Puig P, Gryfe R, Shepherd LE, et al: Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 349:247–257. 2003. View Article : Google Scholar

Schee K, Boye K, Abrahamsen TW, Fodstad Ø and Flatmark K: Clinical relevance of microRNA miR-21, miR-31, miR-92a, miR-101, miR-106a and miR-145 in colorectal cancer. BMC Cancer. 12:5052012. View Article : Google Scholar

Xuan Y, Yang H, Zhao L, Lau WB, Lau B, Ren N, Hu Y, Yi T, Zhao X, Zhou S and Wei Y: MicroRNAs in colorectal cancer: Small molecules with big functions. Cancer Lett. 360:89–105. 2015. View Article : Google Scholar

Shen WW, Zeng Z, Zhu WX and Fu GH: MiR-142-3p functions as a tumor suppressor by targeting CD133, ABCG2, and Lgr5 in colon cancer cells. J Mol Med (Berl). 91:989–1000. 2013. View Article : Google Scholar

Liu X, Wang Y and Zhao J: MicroRNA-337 inhibits colorectal cancer progression by directly targeting KRAS and suppressing the AKT and ERK pathways. Oncol Rep. 38:3187–3196. 2017. View Article : Google Scholar

Wen L, Li Y, Jiang Z, Zhang Y, Yang B and Han F: miR-944 inhibits cell migration and invasion by targeting MACC1 in colorectal cancer. Oncol Rep. 37:3415–3422. 2017. View Article : Google Scholar

Dai H, Hou K, Cai Z, Zhou Q and Zhu S: Low-level miR-646 in colorectal cancer inhibits cell proliferation and migration by targeting NOB1 expression. Oncol Lett. 14:6708–6714. 2017.

Xu Y, Chen J, Gao C, Zhu D, Xu X, Wu C and Jiang J: MicroRNA-497 inhibits tumor growth through targeting insulin receptor substrate 1 in colorectal cancer. Oncol Lett. 14:6379–6386. 2017.

Yang IP, Tsai HL, Miao ZF, Huang CW, Kuo CH, Wu JY, Wang WM, Juo SH and Wang JY: Development of a deregulating microRNA panel for the detection of early relapse in postoperative colorectal cancer patients. J Transl Med. 14:1082016. View Article : Google Scholar

Bovell LC, Shanmugam C, Putcha BD, Katkoori VR, Zhang B, Bae S, Singh KP, Grizzle WE and Manne U: The prognostic value of microRNAs varies with patient race/ethnicity and stage of colorectal cancer. Clin Cancer Res. 19:3955–3965. 2013. View Article : Google Scholar

Peng Q, Zhang X, Min M, Zou L, Shen P and Zhu Y: The clinical role of microRNA-21 as a promising biomarker in the diagnosis and prognosis of colorectal cancer: A systematic review and meta-analysis. Oncotarget. 8:44893–44909. 2017.

Cao J, Yan XR, Liu T, Han XB, Yu JJ, Liu SH and Wang LB: MicroRNA-552 promotes tumor cell proliferation and migration by directly targeting DACH1 via the Wnt/β-catenin signaling pathway in colorectal cancer. Oncol Lett. 14:3795–3802. 2017. View Article : Google Scholar

Cheng D, Zhao S, Tang H, Zhang D, Sun H, Yu F, Jiang W, Yue B, Wang J, Zhang M, et al: MicroRNA-20a-5p promotes colorectal cancer invasion and metastasis by downregulating Smad4. Oncotarget. 7:45199–45213. 2016. View Article : Google Scholar

Fukushima Y, Iinuma H, Tsukamoto M, Matsuda K and Hashiguchi Y: Clinical significance of microRNA-21 as a biomarker in each Dukes' stage of colorectal cancer. Oncol Rep. 33:573–582. 2015. View Article : Google Scholar

Shibuya H, Iinuma H, Shimada R, Horiuchi A and Watanabe T: Clinicopathological and prognostic value of microRNA-21 and microRNA-155 in colorectal cancer. Oncology. 79:313–320. 2010. View Article : Google Scholar

Wang LG and Gu J: Serum microRNA-29a is a promising novel marker for early detection of colorectal liver metastasis. Cancer Epidemiol. 36:e61–e67. 2012. View Article : Google Scholar

He PY, Yip WK, Chai BL, Chai BY, Jabar MF, Dusa N, Mohtarrudin N and Seow HF: Inhibition of cell migration and invasion by miR 29a 3p in a colorectal cancer cell line through suppression of CDC42BPA mRNA expression. Oncol Rep. 38:3554–3566. 2017.

Lv ZC, Fan YS, Chen HB and Zhao DW: Investigation of microRNA-155 as a serum diagnostic and prognostic biomarker for colorectal cancer. Tumour Biol. 36:1619–1625. 2015. View Article : Google Scholar

Zhao J, Xu J and Zhang R: MicroRNA-411 inhibits malignant biological behaviours of colorectal cancer cells by directly targeting PIK3R3. Oncol Rep. 39:633–642. 2018.

Park YJ, Park KJ, Park JG, Lee KU, Choe KJ and Kim JP: Prognostic factors in 2230 Korean colorectal cancer patients: Analysis of consecutively operated cases. World J Surg. 23:721–726. 1999. View Article : Google Scholar

Park YJ, Youk EG, Choi HS, Han SU, Park KJ, Lee KU, Choe KJ and Park JG: Experience of 1446 rectal cancer patients in Korea and analysis of prognostic factors. Int J Colorectal Dis. 14:101–106. 1999. View Article : Google Scholar

Wu ZY, Wan J, Zhao G, Peng L, Du JL, Yao Y, Liu QF and Lin HH: Risk factors for local recurrence of middle and lower rectal carcinoma after curative resection. World J Gastroenterol. 14:4805–4809. 2008. View Article : Google Scholar

Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, Somerfield MR, Hayes DF and Bast RC Jr: ASCO: ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 24:5313–5327. 2006. View Article : Google Scholar

Ozawa T, Ishihara S, Kawai K, Nozawa H, Yamaguchi H, Kitayama J and Watanabe T: Prognostic significance of preoperative serum carbohydrate antigen 19-9 in patients with stage IV colorectal cancer. Clin Colorectal Cancer. 15:e157–e163. 2016. View Article : Google Scholar

Tol J, Koopman M, Miller MC, Tibbe A, Cats A, Creemers GJ, Vos AH, Nagtegaal ID, Terstappen LW and Punt CJ: Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents. Ann Oncol. 21:1006–1012. 2010. View Article : Google Scholar

Sastre J, Maestro ML, Gómez-España A, Rivera F, Valladares M, Massuti B, Benavides M, Gallén M, Marcuello E, Abad A, et al: Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: A Spanish Cooperative Group for the Treatment of Digestive Tumors study. Oncologist. 17:947–955. 2012. View Article : Google Scholar

Dinu D, Dobre M, Panaitescu E, Bîrlă R, Iosif C, Hoara P, Caragui A, Boeriu M, Constantinoiu S and Ardeleanu C: Prognostic significance of KRAS gene mutations in colorectal cancer - preliminary study. J Med Life. 7:581–587. 2014.

Peeters M, Douillard JY, Van Cutsem E, Siena S, Zhang K, Williams R and Wiezorek J: Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: Assessment as prognostic and predictive biomarkers of response to panitumumab. J Clin Oncol. 31:759–765. 2013. View Article : Google Scholar

De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, Lamba S, Arena S, Frattini M, Piessevaux H, et al: Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA. 304:1812–1820. 2010. View Article : Google Scholar

Hecht JR, Douillard JY, Schwartzberg L, Grothey A, Kopetz S, Rong A, Oliner KS and Sidhu R: Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer. Cancer Treat Rev. 41:653–659. 2015. View Article : Google Scholar

Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B and Velculescu VE: Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature. 418:9342002. View Article : Google Scholar

Toon CW, Walsh MD, Chou A, Capper D, Clarkson A, Sioson L, Clarke S, Mead S, Walters RJ, Clendenning M, et al: BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch syndrome. Am J Surg Pathol. 37:1592–1602. 2013. View Article : Google Scholar

Kuan SF, Navina S, Cressman KL and Pai RK: Immunohistochemical detection of BRAF V600E mutant protein using the VE1 antibody in colorectal carcinoma is highly concordant with molecular testing but requires rigorous antibody optimization. Hum Pathol. 45:464–472. 2014. View Article : Google Scholar

De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, et al: Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis. Lancet Oncol. 11:753–762. 2010. View Article : Google Scholar

Popat S, Hubner R and Houlston RS: Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 23:609–618. 2005. View Article : Google Scholar

Sargent DJ, Marsoni S, Thibodeau SN, Labianca R, Hamilton SR, Torri V, Monges G, Ribic C, Grothey A and Gallinger S: Confirmation of deficient mismatch repair (dMMR) as a predictive marker for lack of benefit from 5-FU based chemotherapy in stage II and III colon cancer (CC): A pooled molecular reanalysis of randomized chemotherapy trials. J Clin Oncol. 26 15 suppl:40082008. View Article : Google Scholar

Jover R, Zapater P, Castells A, Llor X, Andreu M, Cubiella J, Balaguer F, Sempere L, Xicola RM, Bujanda L, et al: Gastrointestinal Oncology Group of the Spanish Gastroenterological Association: The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status. Eur J Cancer. 45:365–373. 2009. View Article : Google Scholar

Pohl A, El-Khoueiry A, Yang D, Zhang W, Lurje G, Ning Y, Winder T, Hu-Lieskoven S, Iqbal S, Danenberg KD, et al: Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy. Pharmacogenomics J. 13:173–180. 2013. View Article : Google Scholar

Ong CW, Kim LG, Kong HH, Low LY, Iacopetta B, Soong R and Salto-Tellez M: CD133 expression predicts for non-response to chemotherapy in colorectal cancer. Mod Pathol. 23:450–457. 2010. View Article : Google Scholar

Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, Lingner J, Harley CB and Cech TR: Telomerase catalytic subunit homologs from fission yeast and human. Science. 277:955–959. 1997. View Article : Google Scholar

Wu X, Amos CI, Zhu Y, Zhao H, Grossman BH, Shay JW, Luo S, Hong WK and Spitz MR: Telomere dysfunction: a potential cancer predisposition factor. J Natl Cancer Inst. 95:1211–1218. 2003. View Article : Google Scholar

Willeit P, Willeit J, Mayr A, Weger S, Oberhollenzer F, Brandstätter A, Kronenberg F and Kiechl S: Telomere length and risk of incident cancer and cancer mortality. JAMA. 304:69–75. 2010. View Article : Google Scholar

Calado RT and Young NS: Telomere diseases. N Engl J Med. 361:2353–2365. 2009. View Article : Google Scholar

O'Sullivan J, Risques RA, Mandelson MT, Chen L, Brentnall TA, Bronner MP, Macmillan MP, Feng Z, Siebert JR, Potter JD and Rabinovitch PS: Telomere length in the colon declines with age: A relation to colorectal cancer? Cancer Epidemiol Biomarkers Prev. 15:573–577. 2006. View Article : Google Scholar

Raynaud CM, Jang SJ, Nuciforo P, Lantuejoul S, Brambilla E, Mounier N, Olaussen KA, André F, Morat L, Sabatier L and Soria JC: Telomere shortening is correlated with the DNA damage response and telomeric protein down-regulation in colorectal preneoplastic lesions. Ann Oncol. 19:1875–1881. 2008. View Article : Google Scholar

Aghagolzadeh P and Radpour R: New trends in molecular and cellular biomarker discovery for colorectal cancer. World J Gastroenterol. 22:5678–5693. 2016. View Article : Google Scholar

Fernández-Marcelo T, Sánchez-Pernaute A, Pascua I, De Juan C, Head J, Torres-García A-J and Iniesta P: Clinical relevance of telomere status and telomerase activity in colorectal cancer. PLoS One. 11:e01496262016. View Article : Google Scholar

Gertler R, Rosenberg R, Stricker D, Friederichs J, Hoos A, Werner M, Ulm K, Holzmann B, Nekarda H and Siewert JR: Telomere length and human telomerase reverse transcriptase expression as markers for progression and prognosis of colorectal carcinoma. J Clin Oncol. 22:1807–1814. 2004. View Article : Google Scholar

Norppa H and Falck GC: What do human micronuclei contain? Mutagenesis. 18:221–233. 2003. View Article : Google Scholar

Farhadi S and Mohamadi M and Mohamadi M: Repair index in examination of nuclear changes in the buccal mucosa of smokers: a useful method for screening of oral cancer. Asian Pac J Cancer Prev. 18:3087–3090. 2017.

El-Zein RA, Abdel-Rahman S, Santee KJ, Yu R and Shete S: Identification of small and non-small cell lung cancer markers in peripheral blood using cytokinesis-blocked micronucleus and spectral karyotyping assays. Cytogenet Genome Res. 152:122–131. 2017. View Article : Google Scholar

Maffei F, Moraga Zolezzi JM, Angelini S, Zenesini C, Musti M, Festi D, Cantelli-Forti G and Hrelia P: Micronucleus frequency in human peripheral blood lymphocytes as a biomarker for the early detection of colorectal cancer risk. Mutagenesis. 29:221–225. 2014. View Article : Google Scholar

Karaman A, Binici DN, Kabalar ME and Calikuşu Z: Micronucleus analysis in patients with colorectal adenocarcinoma and colorectal polyps. World J Gastroenterol. 14:6835–6839. 2008. View Article : Google Scholar

Ravegnini G, Moraga Zolezzi JM, Maffei F, Musti M, Zenesini C, Simeon V, Sammarini G, Festi D, Hrelia P and Angelini S: Simultaneous analysis of SEPT9 promoter methylation status, micronuclei frequency, and folate-related gene polymorphisms: The potential for a novel blood-based colorectal cancer biomarker. Int J Mol Sci. 16:28486–284897. 2015. View Article : Google Scholar

Ionescu EM, Nicolaie T, Ionescu MA, Becheanu G, Andrei F, Diculescu M and Ciocirlan M: Predictive cytogenetic biomarkers for colorectal neoplasia in medium risk patients. J Med Life. 8:398–403. 2015.

Kronborg O, Jørgensen OD, Fenger C and Rasmussen M: Randomized study of biennial screening with a faecal occult blood test: Results after nine screening rounds. Scand J Gastroenterol. 39:846–851. 2004. View Article : Google Scholar

Scholefield JH, Moss S, Sufi F, Mangham CM and Hardcastle JD: Effect of faecal occult blood screening on mortality from colorectal cancer: Results from a randomised controlled trial. Gut. 50:840–844. 2002. View Article : Google Scholar

Health Quality Ontario, . Fecal occult blood test for colorectal cancer screening: An evidence-based analysis. Ont Health Technol Assess Ser. 9:1–40. 2009.

Dancourt V, Lejeune C, Lepage C, Gailliard MC, Meny B and Faivre J: Immunochemical faecal occult blood tests are superior to guaiac-based tests for the detection of colorectal neoplasms. Eur J Cancer. 44:2254–2258. 2008. View Article : Google Scholar

Faivre J, Dancourt V, Denis B, Dorval E, Piette C, Perrin P, Bidan JM, Jard C, Jung S, Levillain R, et al: Comparison between a guaiac and three immunochemical faecal occult blood tests in screening for colorectal cancer. Eur J Cancer. 48:2969–2976. 2012. View Article : Google Scholar

Lin JS, Piper MA, Perdue LA, Rutter CM, Webber EM, O'Connor E, Smith N and Whitlock EP: Screening for colorectal cancer: Updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 315:2576–2594. 2016. View Article : Google Scholar

Koo S, Neilson LJ, Von Wagner C and Rees CJ: The NHS bowel cancer screening program: Current perspectives on strategies for improvement. Risk Manag Healthc Policy. 10:177–187. 2017. View Article : Google Scholar

Moss S, Mathews C, Day TJ, Smith S, Seaman HE, Snowball J and Halloran SP: Increased uptake and improved outcomes of bowel cancer screening with a faecal immunochemical test: Results from a pilot study within the national screening programme in England. Gut. 66:1631–1644. 2017. View Article : Google Scholar

Rozen P, Levi Z, Hazazi R, Waked A, Vilkin A, Maoz E, Birkenfeld S and Niv Y: Quantitative colonoscopic evaluation of relative efficiencies of an immunochemical faecal occult blood test and a sensitive guaiac test for detecting significant colorectal neoplasms. Aliment Pharmacol Ther. 29:450–457. 2009. View Article : Google Scholar

Hoffman RM, Steel S, Yee EFT, Massie L, Schrader RM and Murata GH: Colorectal cancer screening adherence is higher with fecal immunochemical tests than guaiac-based fecal occult blood tests: A randomized, controlled trial. Prev Med. 50:297–299. 2010. View Article : Google Scholar

Brenner H and Tao S: Superior diagnostic performance of faecal immunochemical tests for haemoglobin in a head-to-head comparison with guaiac based faecal occult blood test among 2235 participants of screening colonoscopy. Eur J Cancer. 49:3049–3054. 2013. View Article : Google Scholar

Fitzpatrick-Lewis D, Ali MU, Warren R, Kenny M, Sherifali D and Raina P: Screening for colorectal cancer: A systematic review and meta-analysis. Clin Colorectal Cancer. 15:298–313. 2016. View Article : Google Scholar

Murphy J, Halloran S and Gray A: Cost-effectiveness of the faecal immunochemical test at a range of positivity thresholds compared with the guaiac faecal occult blood test in the NHS Bowel Cancer Screening Programme in England. BMJ Open. 7:e0171862017. View Article : Google Scholar

Lee JK, Liles EG, Bent S, Levin TR and Corley DA: Accuracy of fecal immunochemical tests for colorectal cancer: Systematic review and meta-analysis. Ann Intern Med. 160:1712014. View Article : Google Scholar